<DOC>
	<DOCNO>NCT02924909</DOCNO>
	<brief_summary>Phase II trial induction chemotherapy carboplatin AUC 6 plus paclitaxel 175 mg/m2 21 day cycle two cycle follow radiotherapy 4500 cGy 25 fraction plus carboplatin AUC=2 paclitaxel 50 mg/m2 week regimen follow minimally invasive surgery 6 10 week . A PET scan perform time randomization 14 day de first cycle determine relation metabolic response survival .</brief_summary>
	<brief_title>Phase II Trial Neoadjuvant Treatment Minimal Invasive Surgery Esophageal GEJ Cancer</brief_title>
	<detailed_description>Phase II trial induction chemotherapy carboplatin AUC 6 plus paclitaxel 175 mg/m2 21 day cycle two cycle follow radiotherapy 4500 cGy 25 fraction plus carboplatin AUC=2 paclitaxel 50 mg/m2 week regimen follow minimally invasive surgery 6 10 week . A PET scan perform time randomization 14 day de first cycle determine relation metabolic response survival . The primary endpoint evaluate number complete pathologic response . The secondary endpoint evaluation toxicity , radiologic response , metabolic response , result minimally invasive surgery ( blood lose , number conversion open surgery , type resection , R0 , 1 2 , post-op complication , time hospitalization , 30 day post-op mortality ) , evaluate viability treatment protocol ( number patient complete phase ) , evaluate quality life treatment surgery . Inclusion criterias : Histologically proven adenocarcinoma squamous cell carcinoma middle low third esophagus ( included tumor locate gastro-esophageal junction Siewert I II ) , age 18 75 year , Performance Status 0 1 , neutrophil count &gt; 1500/mm3 , platelet count &gt; 100.000/mm3 , hemoglobin count &gt; 9 g/dL , preserve hepatic renal function , stage ( TNM AJCC 7th edition ) : cT1b-3 , N0-1 , M0 , signature inform consent . Exclusion criterias : history another cancer , except skin non melanoma , pregnancy history hypersensitivity study drug</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven adenocarcinoma squamous cell carcinoma middle low third esophagus ( included tumor locate gastroesophageal junction Siewert I II ) Age 18 75 year Performance Status 0 1 Stage ( TNM AJCC 7th edition ) : cT1b3 , N01 , M0 History another cancer , except skin non melanoma Pregnancy History hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>